Business Context and Reporting Period
This Form 8-K Current Report was filed by Caribou Biosciences, Inc. on August 24, 2021. The report details corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from four to five members.
- New Appointment: Nancy C. Whiting, Pharm. D., was appointed as a Class II director and accepted the offer on August 24, 2021.
- Committee Assignment: Dr. Whiting was appointed to the Compensation Committee.
Compensation and Governance Details
In accordance with the Company's Non-Employee Director Compensation Policy, Dr. Whiting's compensation package includes:
- Base Cash Compensation: $40,000 per year for Board service.
- Committee Fee: $5,000 for service on the Compensation Committee.
- Equity: Eligibility for annual grants of equity awards pursuant to the Policy.
Dr. Whiting also entered into a standard indemnification agreement with the Company. The filing confirms no family relationships exist between Dr. Whiting and other directors or officers, and no undisclosed arrangements influenced her election.
Investor Verification Checklist
- Verify the effective date of Dr. Whiting's appointment (August 24, 2021).
- Confirm the total annual cash compensation ($45,000) and equity eligibility under the current policy.
- Review the press release dated August 25, 2021 (Exhibit 99.1) for additional context on the appointment.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.